Earlier this week, BioAge said in a filing it was looking to offer 10.5M shares priced between $17 and $19 per share.The company also anticipated concurrently privately placing $10.6M of its ...

RICHMOND, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic ...

SAN FRANCISCO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who ...

THE LAWSUIT: This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge's registration statement for the initial public offering held on or about September ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. BioAge Labs said it is terminating a mid-stage study of its obesity drug candidate azelaprag in ...